Development and series production of a special instrument for realization of extrahepatic biliary tract surgery with the use of laser surgery units Skalpel-1, Romashka-1 and Romashka-2 is planned for 1987. It will expand the possibilities of biliary tract laser surgery and increase the effect of surgical interventions.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Age-period-cohort analysis of gallbladder and biliary diseases epidemiological trends from 1990 to 2021 and forecasts for 2035: a systematic analysis from the global burden of disease study 2021.
BMC Gastroenterol
January 2025
Department of Gastroenterology, The First Affiliated Hospital of Shihezi University, No.107 North Second Road, Hongshan Street, Shihezi, 832008, China.
Background: Gallbladder and biliary diseases (GABD) represent prevalent disorders of the digestive system.
Methods: Data on age-standardized incidence rate (ASIR), age-standardized mortality rate (ASMR), and age-standardized disability-adjusted life years (DALYs) rate (ASDR) were extracted from the Global Burden of Disease (GBD) 2021 study. The estimated annual percentage change (EAPC) was utilized to quantify temporal trends in GABD.
Subcutaneous adipose tissue radiodensity as a predictor of poor prognosis in advanced biliary tract cancer.
J Hepatobiliary Pancreat Sci
January 2025
Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan.
Background: High subcutaneous adipose tissue radiodensity (SATr), an indirect surrogate marker of adipose tissue quality, was associated with poor prognosis in various cancers. The present study aimed to assess the association of SATr with survival outcomes in patients with advanced biliary tract cancer (BTC).
Methods: This retrospective, single-center study included patients with unresectable or recurrent BTC who underwent chemotherapy/chemoradiotherapy.
Assessment of heterogeneity according to hospital or medical experience factors in outcomes of chemotherapy for advanced biliary tract cancer: a post-hoc analysis of JCOG1113.
Jpn J Clin Oncol
January 2025
Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Background: JCOG1113 is a randomized phase III trial that showed non-inferiority of gemcitabine plus S-1 to gemcitabine plus cisplatin in patients with advanced biliary tract cancer. Assessment of inter-institutional heterogeneity in chemotherapy contributes to confirm generalizability and reliability of the study itself. However, there have been no studies conducted to assess the heterogeneity among participating centers in randomized phase III trials for biliary tract cancer.
View Article and Find Full Text PDFDelayed migration of cystogastrostomy plastic stents managed conservatively.
BMJ Case Rep
January 2025
Department of Internal Medicine, Mayo Clinic, Jacksonville, Florida, USA
Molecular Profiling of Biliary Tract Cancers in African American and Caucasian Patients.
JCO Precis Oncol
January 2025
MD Anderson Cancer Center, Houston, TX.
Purpose: Biliary tract cancers (BTCs) include intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (ECC), and gallbladder cancers. BTCs have a number of genomic alterations, including isocitrate dehydrogenase 1 () mutations, fibroblast growth factor receptor 2 () rearrangements, and amplifications. Therapies targeting these alterations have shown clinical benefit in patients with BTCs in the United States.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!